A carregar...
Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
BACKGROUND: Biosimilar versions of widely prescribed drugs, including the tumour‐necrosis factor antagonist infliximab, are becoming increasingly available. As biosimilars are not identical copies of reference products, evidence may be required to demonstrate that switching between a reference biolo...
Na minha lista:
| Publicado no: | Aliment Pharmacol Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6587715/ https://ncbi.nlm.nih.gov/pubmed/30411382 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.14997 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|